

CATEGORY 1

REGULATOR INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 9702260437	DOC. DATE: 97/02/20	NOTARIZED: NO	DOCKET #
FACIL: 50-250 Turkey Point Plant, Unit 3, Florida Power and Light Co.			05000250
50-251 Turkey Point Plant, Unit 4, Florida Power and Light Co.			05000251
50-335 St. Lucie Plant, Unit 1, Florida Power & Light Co.			05000335
50-389 St. Lucie Plant, Unit 2, Florida Power & Light Co.			05000389

AUTH. NAME	AUTHOR AFFILIATION
PADUANO, H.N.	Florida Power & Light Co.
RECIP. NAME	RECIPIENT AFFILIATION
	Document Control Branch (Document Control Desk)

SUBJECT: Submits 10CFR26 unsatisfactory performance testing incident rept.

DISTRIBUTION CODE: A022D COPIES RECEIVED: LTR 1 ENCL 1 SIZE: 2
 TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES:

	RECIPIENT ID CODE/NAME	COPIES LTTR ENCL	RECIPIENT ID CODE/NAME	COPIES LTTR ENCL
	PD2-3 PD	1 1	CROTEAU, R	1 1
	WIENS, L.	1 1		
INTERNAL:	ACRS	1 1	<u>FILE CENTER</u> 01	1 1
	NRR/DRPM/PERB	1 1	NRR/DRPM/PSGB	1 1
	NUDOCS-ABSTRACT	1 1	RGN2	1 1
EXTERNAL:	NOAC	1 1	NRC PDR	1 1

NOTE TO ALL "RIDS" RECIPIENTS:
 PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK,
 ROOM OWFN 5D-5 (EXT. 415-2083) TO ELIMINATE YOUR NAME FROM
 DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTTR 11 ENCL 11

MATE

C
A
T
E
G
O
R
Y

1

D
O
C
U
M
E
N
T

1/2



FPL

Florida Power & Light Company, P.O. Box 14000, Juno Beach, FL 33408-0420

FEB 20 1997

L-97-29
10 CFR 26


U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, DC 20555

Re: Turkey Point Units 3 and 4
Docket Nos. 50-250 and 50-251
St. Lucie Units 1 and 2
Docket Nos. 50-335 and 50-389
10 CFR 26 Unsatisfactory Performance
Testing Incident Report

Pursuant to 10 CFR 26, Appendix A, Section 2.8(e)(4), Florida Power and Light Company (FPL) is submitting to the NRC the enclosed report of an unsatisfactory performance testing incident. FPL submitted blind performance test specimens to FPL's contract Department of Health and Human Services (DHHS) certified laboratory, SmithKline Beecham Clinical Laboratories. The enclosed report summarizes the investigative analysis of the unsatisfactory blind specimen result, the identification of the cause, and the corrective action taken by the laboratory to prevent recurrence.

Please contact us if additional information is required.

Very truly yours,


H. N. Paduano
Manager
Licensing and Special Programs

HNP/spt

Attachment

260007

cc: Regional Administrator, Region II, USNRC
Senior Resident Inspector, USNRC, Turkey Point Plant
Senior Resident Inspector, USNRC, St. Lucie Plant

9702260437 970220
PDR ADOCK 05000250
P PDR

1944

1944

SB
SmithKline Beecham
Clinical Laboratories

January 24, 1997

Dr. Amy Feder
Medical Review Officer
Florida Power & Light
700 Universe Blvd, Ste D02224
Juno Beach, FL 34408

RE: 530-35-9944

Dear Dr. Feder:


I believe the final resolution to the blind sample performance issue has been completed. A summary of that investigation and corrective action follows.

1. The specimen was received in Leesburg on 11/26/96
2. The specimen was determined to be presumptively positive for opiates, and therefore poured for GC/MS confirmation.
3. The specimen was diluted X5 as a result of the high absorbance value.
4. The specimen did show some morphine, but the ion ratios were not in the acceptable range.
5. The sample was reextracted and showed the correct result.
6. The investigation into the matter showed that if the sample has been reextracted at a somewhat less dilution, the morphine value would have been determined.
7. The SOP manual was changed to reflect this approach, and all positive certifiers were trained in this aspect of review.
8. The investigation was closed with this change to the SOP manual, and the retraining of personnel was completed on January 22, 1997.

Copies of all correspondence had been previously sent under separate cover. I sincerely hope that this is the last occurrence of this nature.

Thank you for your patience and consideration in this matter.

Respectively submitted,


Michael I. Schaffer, Ph.D., D.A.B.F.T.
Director of Toxicology

MIS/jb

